The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% since 2005. The report forecasts this growth to slow down considerably to a CAGR of 5.6% between 2008 and 2018 mainly due to maturing markets and the entry of generics for several key products. Sales of the Top 20 brands are expected to reach a total of $940m in 2018.

Reasons to Purchase

* Identify key opportunities and threats that will impact the Australian oncology market as a whole and the Top 20 in particular
* Quantify the future size and scope of the Top 20 Australian cancer therapies market and predict the performance of its key compounds
* Understand critical success factors in growing and defending cancer brand franchises from new entrants and generics

Key Chapters of The Report :

OVERVIEW
Introduction
Scope of this research
Research and analysis highlights
Datamonitor forecasts that the molecular targeted therapies will continue to drive growth in the Australian Top 20 cancer therapies market over the forecast period 2008–2018, with sales increasing from $320m in 2008 to $750m 2018.
Key reasons to read this report
Forecasting Methodology
The forecasting model:
General event information:
Event selection and quantification:
Event parameters:

Get more information about this report: Top 20 Cancer Therapy Brands in Australia Forecast

Find Market Research Reports

Check our Company Profiles and Country Reports

Bharat Book Bureau
Email: sandhya@bharatbook.com
Tel: +91 22 27578668
Fax: +91 22 27579131